pharma news

News

Kailera, Hengrui stake claim to oral weight loss category

Chasing Novo Nordisk and Eli Lilly, Kailera and Hengrui have reported 12.1% weight loss in phase 2 with their oral GIP/GLP-1 agonist ribupatide.

News

AstraZeneca raises guidance on stellar cancer drugs growth

AZ reports strong financial results for 2025, and provides a first peek at the data for its oral GLP-1 contender elecoglipron.

News

Takeda signs $1.7bn AI alliance with Iambic

Iambic bags another pharma partner, Takeda, which plans to use its AI platform to find drugs for cancer, gastrointestinal, and inflammatory disorders.

News

Curran Simpson, Regenxbio's president and CEO

Dismay as FDA blocks Regenxbio's Hunter syndrome therapy

The FDA said it needs more information before it can approve Regenxbio's gene therapy for Hunter syndrome, in a devastating decision for patients.

News

Lupin settles Myrbetriq patent spat with Astellas for $90m

Lupin will be able to keep its generic of Astellas' overactive bladder therapy Myrbetriq on the US market, after reaching a settlement agreement.

News

Lilly strikes again, buying CAR-T firm Orna for $2.4bn

In its second major deal in two days, Eli Lilly has reached an agreement to buy in vivo CAR-T developer Orna Therapeutics for up to $2.4bn.

Kailera, Hengrui stake claim to oral weight loss category

AstraZeneca raises guidance on stellar cancer drugs growth

Takeda signs $1.7bn AI alliance with Iambic

Dismay as FDA blocks Regenxbio's Hunter syndrome therapy

Lupin settles Myrbetriq patent spat with Astellas for $90m

Lilly strikes again, buying CAR-T firm Orna for $2.4bn

EU clears first drug therapy for rare disease cALD

Discover a new era of healthcare panel engagement: Grounded ...

pharma news

Editor's Picks